Results 81 to 90 of about 5,449 (190)

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study

, 2021
International audienceCefiderocol is a novel siderophore cephalosporin, which has proven in vitro activity against carbapenem-resistant (CR) Gram-negative pathogens and stability towards all carbapenemases. The aim of this study was to describe the first
Mihaila, Liliana, Dinh, Aurélien, Clara Duran, Benjamin Wyplosz, Duran, Clara, Tattevin, Pierre, Razazi, Keyvan, Remy Bonnin, Vincent Bunel, Sophie-Caroline Sacleux, Dortet, Laurent, Helga Junot, Dupont, Hervé, Sacleux, Sophie-Caroline, Remy A. Bonnin, Nathalie Grall, Keyvan Razazi, Aurélien Dinh, Wyplosz, Benjamin, S, Bunel, Vincent, Bleibtreu, Alexandre, Laurent Dortet, Pierre Tattevin, Hervé Dupont, Grall, Nathalie, on behalf of the Cefiderocol French Study Group, Junot, Helga, Alexandre Bleibtreu, Bonnin, Rémy, Liliana Mihaila   +29 more
core   +1 more source

Cefiderocol susceptibility and carbapenemase profiles in carbapenem-resistant Enterobacterales.

Objective: Cefiderocol is a siderophore cephalosporin used as a last resort treatment for infections caused by carbapenem-resistant Enterobacterales (CRE), which pose a threat to public health.
Bayrak, Ayça, Çakıcı, Nesrin, Mutlu, Reyhan, Akçalı, Alper   +3 more
core   +1 more source

Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints

, 2023
Cefiderocol is generally active against carbapenem-resistant Klebsiella spp. (CRK) with higher MICs against metallo-beta-lactamase producers. There is a variation in cefiderocol interpretive criteria determined by EUCAST and CLSI.
Funda Şimşek (16476969), Şirin Menekşe (16476978), Özlem Azap (16477023), Cansel Vatansever (16476960), Güle Çınar (14277797), Veli Oğuzalp Bakır (16477014), Abdullah Tarık Aslan (16476966), İlker İnanç Balkan (16476984), Çiğdem Arabacı (16477005), Alpay Azap (16477020), Mehtap Aydın (16476987), Brian Forde (3806995), Michelle J. Bauer (11011758), Gülşen Hazırolan (16477011), Safiye Koçulu Demir (16476993), Necla Tülek (16476972), Serap Yağcı (16477008), Özlem Doğan (16477002), Mehmet Gönen (5641580), Burcu Isler (8460285), Halis Akalin (16476981), Neşe Saltoğlu (16477017), Şiran Keske (16476999), Murat Akova (11220478), Elif Tükenmez Tigen (16476990), Patrick N. A. Harris (2623102), Hamiyet Demirkaya (16476975), Önder Ergönül (5641574), Caitlin Falconer (8159034), Mahir Kapmaz (16476996), David L. Paterson (124677), Berna Özer (16476963), Füsun Can (16477026)   +32 more
core   +1 more source

When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada

Microbiology Spectrum
Gram-negative metallo-β-lactamase-producing bacteria can be extremely problematic, especially when found to be extensively drug-resistant (XDR). Cefiderocol is a novel antimicrobial that has been shown to overcome most carbapenemases, with very rare ...
Kevin R. Barker, Gabriel W. Rebick, Ken Fakharuddin, Clayton MacDonald, Michael R. Mulvey, Laura F. Mataseje   +5 more
doaj   +1 more source

Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study

Antibiotics
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) poses significant challenges in healthcare due to its multidrug resistance and high mortality rates among critically ill patients. Results: We enrolled 45 patients.
Antonio Riccardo Buonomo, Riccardo Scotto, Nunzia Esposito, Giulio Viceconte, Nicola Schiano Moriello, Giulia Zumbo, Ilaria Vecchietti, Amedeo Lanzardo, Carmine Iacovazzo, Francesco Curcio, Emanuela Roscetto, Ivan Gentile   +11 more
doaj   +1 more source

Cefiderocol in Difficult-to-Treat Nf-GNB in ICU Settings

Background The efficacy and safety of cefiderocol in ICU patients with difficult-to-treat resistance (DTR) non-fermenting Gram-negative bacteria (Nf-GNB) are not as well-established.
Jean Christophe Richard, Friggeri, Arnaud, Olivier Dauwalder, Kaas, Anne, Anne Kaas, Charles-Hervé Vacheron, Anne-Claire Lukaszewicz, Florent Wallet, Argaud, Laurent, Fellahi, Jean-Luc, Richard, Jean Christophe, Rasigade, Jean-Philippe, Frederic Aubrun, Aubrun, Frederic, Jean-Philippe Rasigade, Balanca, Baptiste, Jean-Luc Fellahi, Arnaud Friggeri, Laurent Argaud, Dauwalder, Olivier, Baptiste Balanca, Lukaszewicz, Anne-Claire, Wallet, Florent, Vacheron, Charles-Hervé   +23 more
core   +1 more source

PiuA promoter mutations confer cefiderocol resistance in Acinetobacter baumannii: from in vitro evolution to global genomic screening

Frontiers in Microbiology
IntroductionCarbapenem-resistant Acinetobacter baumannii (CRAB) poses a global health threat due to limited therapeutic options. Cefiderocol, a novel siderophore-conjugated cephalosporin, demonstrates potent in vitro activity against a variety of Gram ...
Xiaochen Liu, Qingye Xu, Jintao He, Wang Zhang, Sebastian Leptihn, Sebastian Leptihn, Peng Lan, Yunxing Yang, Yunsong Yu, Yunsong Yu, Xiaoting Hua, Xiaoting Hua, Meng Li   +12 more
doaj   +1 more source

Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus

International audienceBackground : Cefiderocol is a siderophore-conjugated cephalosporin increasingly used in the management of Achromobacter infections. Testing for cefiderocol susceptibility is challenging with distinct recommendations depending on the
Sorlin, Pauline, Pantel, Alix, Marchandin, H., Chiron, Raphaël, Lavigne, Jean-Philippe, Jean-Pierre, Vincent, Jeannot, Katy   +6 more
core   +1 more source

The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis Is Dependent upon the State of the Corneal Epithelium

Antibiotics
Background: An overlooked factor in the efficacy of topical antibiotics to treat bacterial keratitis is the state of the corneal epithelium. Recently, we evaluated topical cefiderocol for the treatment of extensively drug-resistant (XDR) Pseudomonas ...
Eric G. Romanowski, Jonathan B. Mandell, Vishal Jhanji, Robert M.Q. Shanks   +3 more
doaj   +1 more source

Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and Resistance

Acinetobacter baumannii (A. baumannii) has emerged as a prominent multidrug-resistant (MDR) pathogen, significantly complicating treatment strategies due to its formidable resistance mechanisms, particularly against carbapenems.
Shima Asli, Valentyn Oksenych, Payman Mazaheri, Amir Hosein Gorgin, Setayesh Kashanipoor, Ali Babaeizad, Tahereh Alipour, Sina Mohammadi, Majid Eslami, Farnaz Alibabaei, Bahman Yousefi   +10 more
core   +1 more source